Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NQO1 | P15559 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10372134 | 0.88 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDTP53 | |
| SCHEMBL5734812 | 0.86 | KDM4E (0.72) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL6234986 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL4763073 | 0.84 | KDM4E (0.78) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL3375173 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL28292562 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL8702456 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL6720336 | 0.81 | NQO1 (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL7001218 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL6240452 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644364-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH PI3K ACTIVITY AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050020631-A1 | 3-Substituted benzofurans as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108709-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH P13K AKTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-0187487-B1 | BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGIC ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4703053-A | Benzothiophenes and benzofurans and antiallergic use thereof | WARNER-LAMBERT COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0187487-A1 | Benzothiophenes and benzofurans having antiallergic activity | WARNER-LAMBERT COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020631-A1 | 3-Substituted benzofurans as therapeutic agents | CYP4F11, BPTF, F3 | KDM4E 2213/4885ALDH1A1 103/4885SMN1; SMN2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.